Therapy News and Research

RSS

Cellular mechanosensory system may yield new insights for cancer therapy

Every moment, millions of a body's cells flawlessly divvy up their genes and pinch perfectly in half to form two identical progeny for the replenishment of tissues and organs - even as they collide, get stuck, and squeeze through infinitesimally small spaces that distort their shapes.

11 Sep 2009

Amylin and Biocon collaborate to develop a peptide therapeutic for treating diabetes

Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) and Biocon, Limited (NSE: BIOCON) announced today that they have entered into an exclusive agreement to jointly develop, commercialize and manufacture a novel peptide therapeutic for the potential treatment of diabetes. Amylin and Biocon will collaborate to develop the therapeutic potential of the compound and share development costs. Research will center on Amylin's "phybrid" technology.

11 Sep 2009

Positive results from Mpex' Phase 2b clinical trial with Aeroquin

Mpex Pharmaceuticals, Inc. today announced positive data from its Phase 2b clinical trial with Aeroquin((R)) (a novel aerosol formulation of levofloxacin, MP-376) in cystic fibrosis (CF). Trial results showed that nebulized Aeroquin met the primary endpoint of reducing bacterial counts of Pseudomonas aeruginosa (P. aeruginosa) in sputum after 28 days of dosing versus placebo.

11 Sep 2009

Phase 3 trial of ataluren commences

PTC Therapeutics, Inc. (PTC) today announced the initiation of a Phase 3 trial of ataluren (formerly PTC124(R)), an investigational protein restoration therapy in patients with nonsense mutation cystic fibrosis (nmCF).

11 Sep 2009

New data reveals the efficacy of Instanyl in management of breakthrough cancer pain

New data presented today further demonstrate the efficacy of Instanyl in management of breakthrough cancer pain. The data which were presented at the 6th congress of the European Federation of Chapters of the International Association for the Study of Pain (EFIC) are from a multinational, crossover trial comparing Instanyl with oral transmucosal fentanyl citrate (OTFC) for the treatment of breakthrough pain in patients with cancer.

11 Sep 2009

TomoTherapy signs purchasing agreement with GNYHA Services

TomoTherapy Incorporated, maker of the TomoTherapy® treatment system for advanced, CT-guided radiation therapy, announced today that it has signed an equipment supply group purchasing agreement with GNYHA Services, Inc. Pursuant to this agreement, TomoTherapy technology will be made available at contracted rates to more than 220 member hospitals in New York, New Jersey, Pennsylvania and Puerto Rico.

11 Sep 2009

Efficacy of Instanyl in management of breakthrough cancer pain demonstrated

11 Sep 2009

Second-hand tobacco smoke exposure results in NAFLD

A team of scientists at the University of California, Riverside has found that even second-hand tobacco smoke exposure can result in nonalcoholic fatty liver disease (NAFLD), a common disease and rising cause of chronic liver injury in which fat accumulates in the liver of people who drink little or no alcohol.

11 Sep 2009

Universal American allies with Nifty after Fifty

Universal American Corp. is pleased to announce a strategic alliance with Nifty after Fifty(“NaF”), a company that operates health and wellness centers focused primarily on the senior community.

11 Sep 2009

Vitapath Genetics closes $6 million series A round of funding

VitaPath Genetics, a molecular diagnostics company, announced today that it has closed a $6 million series A round of funding led by MDV-Mohr Davidow Ventures. VitaPath was originally seeded by X/Seed Capital, which also co-invested in the Series A. Concurrent with the financing MDV's Michael Goldberg and X/Seed's Michael Borrus took seats on the company's board.

11 Sep 2009

ABTA launches new research program on brain tumor therapy

The American Brain Tumor Association has launched a new Special Projects Discovery Grant program to support fresh and creative research ideas for solving the challenges of brain tumor diagnosis and treatment.

11 Sep 2009

Zevalin radioimmunotherapy drug approved for treating non-Hodgkin's lymphoma

SNM applauds the U.S. Food and Drug Administration's (FDA) recent decision to approve the radioimmunotherapy (RIT) drug, Zevalin, as a front-line treatment of non-Hodgkin's lymphoma (NHL).

11 Sep 2009

Medicare reimbursement cuts will affect cancer care system

The Community Oncology Alliance (COA), a national non-profit organization that represents oncologists and other cancer care providers, strongly opposes cuts in Medicare reimbursement for cancer care outlined by the Centers for Medicare & Medicaid Services (CMS).

11 Sep 2009

Routine screening is useful for identifying pregnant women with gestational diabetes

Pregnant women who develop marked increased blood sugar levels during pregnancy can reduce the risk of certain birth complications if they receive treatment. This is a prerequisite for offering all pregnant women routine screening for gestational diabetes.

11 Sep 2009

Fau and MELK genes may help improve breast cancer diagnosis and treatment

Researchers at Keele University have identified two genes which may help improve the diagnosis and treatment of breast cancer patients.

11 Sep 2009

Phase II human clinical trial of Exsulin commences

Exsulin Corporation today announced the start of a phase II human clinical trial of Exsulin, a peptide drug product aimed at restoring insulin production in people with diabetes mellitus. The randomized, controlled 12-week trial in patients with established Type 1 diabetes (T1DM) will be co-led by Mayo Clinic in Rochester, Minn., and McGill University Health Centre in Montreal, Canada.

10 Sep 2009

FDA approves Supplemental New Drug Application for DOXIL

Centocor Ortho Biotech Products, L.P. today announced that it received a Complete Response letter from the U.S. Food and Drug Administration (FDA) regarding its Supplemental New Drug Application (sNDA) for DOXIL (doxorubicin HCI liposome injection) in combination with docetaxel for the treatment of women with locally advanced and metastatic breast cancer.

10 Sep 2009

Vitro Diagnostics' novel stem cell technology for cancer treatment

Vitro Diagnostics, Inc., dba Vitro Biopharma, announced advances in its adult stem cell products and technology with application to cell-based therapy of cancer. With the passing of Senator Edward Kennedy from brain cancer, we are reminded of such aggressive cancers without effective treatment.

10 Sep 2009

Endothelin research update to be presented at APS' 11th International Conference

Recent research to block the effects of endothelin, a powerful substance that constricts blood vessels and stimulates cell growth, has led to successful treatment of pulmonary arterial hypertension and provides hope for treating other chronic diseases.

10 Sep 2009

Teva's COPAXONE holds promise for relapsing remitting multiple sclerosis

Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) today presented data that demonstrated patients treated for 10 and 15 years with COPAXONE® (glatiramer acetate injection) had significant reduction in disease severity. These data, generated from the longest continuous prospective study of any disease modifying therapy in relapsing remitting multiple sclerosis (RRMS), were presented today at the 25th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Düsseldorf, Germany.

10 Sep 2009